All News

2025

The 2025 Rheumatology Year in Review

Jack Cush, MD

The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.

Read Article
RheumNow Podcast square

2026 Resolutions (1.9.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Read Article
guidelines.recommendations.jpg

Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis

Jack Cush, MD

Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!

Read Article
hospital,surgery

Best of 2025: Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients

Jack Cush, MD

More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the perioperative management of DMARDs and found inconsistencies and low quality evidence, with great reliance on conditional (expert opinion) recommendations.

Read Article
Lindsay Tom

Hidden in Plain Sight: IBD

Lindsay Tom PA-C

As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel disease.

Read Article
DM Cover for Video

I Can't Believe it's Not Seronegative Rheumatoid Arthritis?!

Daric A. Mueller, PA-C

In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis. 

Read Article
Eval of Rheum Complaints Cover Image

Evaluation of Rheumatic Complaints

Jack Cush, MD

Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.

Read Article
labs.tubes_.jpg

British Society of Rheumatology Guideline for Monitoring DMARDs

Jack Cush, MD

The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic autoimmune rheumatic diseases (SARDs). 

Read Article
RheumNow Podcast square

APPs in the News (12.5.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com, including info on scleroderma, dermatomyositis and malignancy, rheumatologist and APP salary concerns.

Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/fxFcqy13g7
Dr. John Cush RheumNow ( View Tweet)
Best of 2025: GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” https://t.co/hFejdS4sjk
Dr. John Cush RheumNow ( View Tweet)
HLA-B27: still the most important genetic factor in axSpA susceptibility, but has lower frequency African American, South American & Middle Eastern pop. B27 discerns clinical subsets of SpA and PsA, particularly acute anterior uveitis or axSpA with psoriasis, https://t.co/Yg7DBOTW8o
Dr. John Cush RheumNow ( View Tweet)
Hidden in Plain Sight: IBD As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel https://t.co/Aatc4jkbpH
Dr. John Cush RheumNow ( View Tweet)
APP QD Clinic: Difficult AxSpA Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/VY0O26l7XC
Dr. John Cush RheumNow ( View Tweet)
GESPIC - German SpA study of 252 SpA (139 nr- axSpA, 113 r-axSpA), followed w/ serial Xrays and mSASS Scores over 2 yrs. 80% were on NSAIDs. Higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA https://t.co/sKgCGaJFVr https://t.co/jMQTAnsCmG

Links:

Dr. John Cush RheumNow ( View Tweet)
The countdown is on! ⏱️ Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one. ✅ Register now at https://t.co/4UQlqwujiR 🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu

Links:

Dr. John Cush RheumNow ( View Tweet)
APP QD Clinic: Difficult AxSpA Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/qlBUtt6zWr
Dr. John Cush RheumNow ( View Tweet)
GESPIC - German SpA study of 252 SpA (139 nr- axSpA, 113 r-axSpA), followed w/ serial Xrays and mSASS Scores over 2 yrs. 80% were on NSAIDs. Higher NSAID intake, particularly COX2i, on slowing radiographic progression in axSpA https://t.co/MfmzWwvtZx https://t.co/5Fe2AQgkN2

Links:

Dr. John Cush RheumNow ( View Tweet)
RNL 25 Replay: Spondyloarthritis Enjoy these excerpts from the RNL 2025 meeting, and join us for RNL 2026 in Dallas, TX - registration is now open! Visit https://t.co/o78Pc8LPsQ for complete details. https://t.co/OuVLKKbA6U https://t.co/zPiuSH47Fg

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×